These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 7710436)
1. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy. Vlcek J; Macek K; Hůlek P; Brátová M; Fendrich Z Arzneimittelforschung; 1995 Feb; 45(2):146-9. PubMed ID: 7710436 [TBL] [Abstract][Full Text] [Related]
2. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Dadashzadeh S; Javadian B; Sadeghian S Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180 [TBL] [Abstract][Full Text] [Related]
3. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Hong SP; Chang KS; Koh YY; Choi DH; Choi JS Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809 [TBL] [Abstract][Full Text] [Related]
4. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. Choi JS; Han HK J Pharm Pharmacol; 2004 Dec; 56(12):1537-42. PubMed ID: 15563760 [TBL] [Abstract][Full Text] [Related]
5. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Kim HJ; Choi JS Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069 [TBL] [Abstract][Full Text] [Related]
6. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Piao YJ; Choi JS Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511 [TBL] [Abstract][Full Text] [Related]
7. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Tannergren C; Engman H; Knutson L; Hedeland M; Bondesson U; Lennernäs H Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508 [TBL] [Abstract][Full Text] [Related]
8. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. Tartaglione TA; Pieper JA; Lopez LL; Mehta J Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470 [TBL] [Abstract][Full Text] [Related]
10. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. Choi JS; Burm JP Arch Pharm Res; 2005 Apr; 28(4):483-7. PubMed ID: 15918524 [TBL] [Abstract][Full Text] [Related]
12. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407 [TBL] [Abstract][Full Text] [Related]
13. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity. Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881 [TBL] [Abstract][Full Text] [Related]
15. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Choi JS; Burm JP Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964 [TBL] [Abstract][Full Text] [Related]
16. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394 [TBL] [Abstract][Full Text] [Related]
18. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446 [TBL] [Abstract][Full Text] [Related]
19. Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations. Horne C; Spahn H; Mutschler E; Knauf H Arzneimittelforschung; 1987 Aug; 37(8):956-9. PubMed ID: 3675692 [TBL] [Abstract][Full Text] [Related]
20. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]